FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to compounds of formula and its pharmaceutically active salts R1 represents hydrogen, halogen n represents 1 or 2, if n represents 2, then R1 can be different R2 represents C2-7-alkyl or C3-6-cycloalkyl R3 represents the group wherein X represents CH R5 represents hydrogen, -C(O)-lower alkyl, -C(O)O-lower alkyl, S(O)2-lower alkyl, -C(O)-CH2-CN, or represents -C(O)-C3-6-cycloalkyl, wherein the cycloalkyl groups can be optionally substituted by a lower alkyl, -CH2-O-lower alkyl, lower alkoxy, CF3, halogen or cyano, or represents -C(O)-(4-6-merous heterocycloalkyl containing 1 heteroatom specified in O, N), or represents -C(O)-(6-merous heteroaryl containing 1-2 heteroatoms N), or represents 6-merous heteroaryl containing 1-2 heteroatoms N, or represents -C(O)-phenyl, wherein heterocycloalkyl, heteroaryl or phenyl groups are optionally substituted by halogen, lower alkyl, =O, lower alkyl substituted by a halogen, lower alkyl substituted by hydroxy, -C(O)-CH2-N(di-lower alkyl), C(O)NH2, -O-C(O)-lower alkyl, C(O)-lower alkyl, S(O)2-lower alkyl or cyano R4 represents phenyl substituted by a halogen. The invention also refers to the compound [(3S,4R)-4-(4-chloro-3-fluoro-phenyl)-1-(1-isopropyl-6-oxo-piperidin-3-carbonyl)-pyrrolidin-3-yl]-ethyl-carbamic acid 4-fluoro-phenyl ester to a medicinal product possessing properties of an NK-3 receptor antagonist, containing one or more compounds of the inventions, and to the use of the compounds for preparing the medicinal product.EFFECT: there are prepared new compounds, which possess the properties of the NK-3 receptor antagonist.8 cl, 1 tbl, 126 exИзобретение относится к соединениям формулы I и его фармацевтически активным солямR1 представляет собой водород, галоген n представляет собой 1 или 2, если n представляет собой 2, то R1 могут различаться R2 представляет собой С2-7-алкил или С3-6-циклоалкил R3 представляет собой группу где X представляет собой СН R5 представля
